Blue Owl Capital Holdings LP Takes Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

Blue Owl Capital Holdings LP purchased a new stake in Structure Therapeutics Inc. (NASDAQ:GPCR) in the 2nd quarter, HoldingsChannel.com reports. The firm purchased 55,000 shares of the company’s stock, valued at approximately $2,160,000. Structure Therapeutics accounts for approximately 0.6% of Blue Owl Capital Holdings LP’s holdings, making the stock its 29th biggest position.

Several other large investors also recently added to or reduced their stakes in GPCR. Sandia Investment Management LP bought a new stake in Structure Therapeutics during the second quarter valued at $39,000. Sectoral Asset Management Inc. bought a new stake in Structure Therapeutics during the fourth quarter valued at $139,000. ADAR1 Capital Management LLC bought a new stake in Structure Therapeutics during the fourth quarter valued at $163,000. Sei Investments Co. bought a new stake in Structure Therapeutics during the second quarter worth about $212,000. Finally, Mather Group LLC. bought a new stake in Structure Therapeutics during the second quarter worth about $214,000. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Price Performance

Shares of NASDAQ:GPCR opened at $41.75 on Friday. Structure Therapeutics Inc. has a 1 year low of $26.61 and a 1 year high of $75.02. The stock’s 50-day moving average is $38.06 and its 200 day moving average is $39.73. The company has a market cap of $1.95 billion, a PE ratio of -54.88 and a beta of -3.52.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. Analysts expect that Structure Therapeutics Inc. will post -0.86 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on GPCR. JMP Securities dropped their price target on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a research note on Friday, August 9th. BMO Capital Markets boosted their target price on Structure Therapeutics from $83.00 to $100.00 and gave the company an “outperform” rating in a research note on Friday, June 7th. Morgan Stanley began coverage on Structure Therapeutics in a research note on Monday, September 23rd. They issued an “overweight” rating and a $118.00 target price for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 target price on shares of Structure Therapeutics in a research note on Monday, September 23rd. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $88.33.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.